Pfizer (PFE) PT Lifted to $41 at BMO Capital on Sum-of-the-Parts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pfizer (PFE) Tops Q2 EPS by 4c
July 28, 2015 7:01 AM EDTPfizer (NYSE: PFE) reported Q2 EPS of $0.56, $0.04 better than the analyst estimate of $0.52. Revenue for the quarter came in at $11 billion versus the consensus estimate of $11.42 billion.
Raised Midpoints of 2015 Financial Guidance Ranges for Reported Revenues by $500 Million and Reported and Adjusted(2) Diluted EPS by $0.03 and $0.04, Respectively, Due to Strong Performance to Date and Improved Business Outlook
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our second-quarter and year-to-date financial performance is the result of continued business... More
